Modeling and Intermolecular Binding Analysis of Novel 5-Aryl-1,3,4-Oxadiazole Derivatives with some Macromolecular Cancer Relevant Targets by رزاقی اصل, نیما et al.
 ‌أ
 
 
 داوشگبٌ علًم پششکی اردبیل
 داوشکذٌ داريسبسی
 
‌ی‌دکتری‌عوَهی‌دارٍسبزیی‌رسبلًِبهِ پبیبى‌‌
 
 عىًان:
اُكسبديبسيل بب بزخی اس -4،3،1آريل -5مذل سبسی ي آوبلیش اتصبل بیه مًلکًلی مشتقبت 
 پزيتئیه َبی مزتبط بب سزطبن
 
راَىمب اسبتیذ  
 اقی اصلدكتز ویمب رسّ
 دكتز علی رمضبوی
 وگبرش
 راديه علیخبوی
 
7/99     56-د    
 
 
99مُز   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
‌ت  
 
 
Ardabil University of Medical Sciences 
School of Pharmacy 
 
 
Title of Dissertation  
Modeling and Intermolecular Binding Analysis of Novel 5-Aryl-1,3,4-
Oxadiazole Derivatives with some Macromolecular Cancer Relevant 
Targets  
 
Supervisors 
Dr. Nima Razzaghi-Asl 
Dr. Ali Ramazani 
By 
Radin Alikhani 
 
 7/99     56-د
 
 
 
 
 
October 2020 
 
‌ج  
 
 
 
 
 …سپاس خدای را که هر چه دارم از اوست
 
 
  :تقدیم به
 عزیزتر از جانم؛ مادرو پدر 
ز عشق چشمانشان اپر  که هر لحظه وجودم را از چشمه سار
 ،کنند سیراب می
 ؛استاد گرانقدرم، دکتر نیما رزاقی اصل
حصیل دانشگاهی من، راهنما و مشوّق تکه در تمام دوران 
 ،ند ه اهمیشگی و بی منّت بود
 ؛علی رمضانی عزیزدکتر 
 که بانی اصلی آغاز این پایان نامه تحقیقاتی بوده اند
  و
پرورشان بدرقه ی راهم  آنان که نفس خیرشان و دعای روحهمه 
 .بود
 
 
 
 
 
‌خ  
 
Acknowledgements 
I would like to deeply thank my parents for their all-time supports and camaraderie. I 
would also like to be grateful to my best supervisor, motivator and friend, Dr. Nima 
Razzaghi-Asl for his kind guides in every aspect of my education and life pathway. 
Supports of this project by Research Council of Ardabil University of Medical Sciences 
are also acknowledged.                                         .
a 
 
Abstract 
Introduction: Cancer, the uncontrollable growth of abnormal cells, is the second leading cause of 
death following cardiovascular diseases. Further progression of basic sciences and introduction of 
novel drug design techniques and possibility of predicting ligand-receptor interactions, has led to 
more attempts to discover, design and develop new anticancer chemicals with the hope of 
accessing to new drugs to complete the cancer treatment process. 1,3,4-Oxadiazole derivatives due 
to their unique chemical structure and biological/pharmacological applications, are known as one 
of the centers of attention in medicinal chemistry. 
 
Materials, Instruments and Methods: A few novel previously synthesized 2,5-disubstituted 
1,3,4-oxadiazole derivatives (1-17) were subjected to combined systematic docking/quantum 
mechanical studies against certain previously proven chemotherapeutic receptors. AutoDock4.2 
and ORCA quantum chemistry packages were used for modeling studies while LigPlot and Viewer 
Lite software were applied for obtaining ligand-target binding patterns.  
 
Results and Discussions: In the current project, it was tried to explore binding modes/affinities of 
experimentally validated 1,3,4-oxadiazoles (1-17), to some validated chemotherapeutic targets. 
Structure binding relationship (SBR) studies showed that chemical structures possessing halogen 
atoms on 5-substituted phenyl and N-benzyl rings (4 and 17) exhibited superior binding 
modes/energies with regard to the majority of studied targets, regardless of their cytotoxic activity. 
A few oxadiazole structures exhibited ΔGbs comparable to or stronger than crystallographic ligands 
that were previously demonstrated to inhibit intended targets. On the basis of obtained results, a 
general SAR/SBR for binding of candidate oxadiazoles to binding sites of relevant targets was 
developed and a few top-ranked 2,5-disubstituted 1,3,4-oxadiazole structures were proposed as 
potential cytotoxic candidates that were also virtually validated. Moreover; lowest binding energy 
in the B3LYP/Def2-SVP level of calculation could be estimated for Arg486 (-6.05 kcal/mol) in 
binding of compound 17 to telomerase.  
 
Conclusion and Suggestions: Various studies have demonstrated 1,3,4-oxadiazole heterocyclic 
nucleus as a privileged medicinal scaffold. A series of novel 2,5-disubstituted 1,3,4-oxadiazole 
derivatives were elucidated for their intermolecular binding patterns with some of the cancer 
relevant oxadiazole-inhibited targets. On the basis of obtained results, a general SAR/SBR pattern 
for candidate 1,3,4-oxadiazoles was offered and some hybrid oxadiazole structures were proposed 
as potential cytotoxic agents. Since the assessed macromolecular targets were previously proved to 
be blocked by 1,3,4-oxadiazoles, the results of this study might be useful in further design of more 
potent anticancer 1,3,4-oxadiazole derivatives through extending the scope of privileged structures 
toward designing new potential anti-tumor compounds. 
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